| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131356A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 09/12/2001 | EP1131349A2 Potassium channel interactors and uses therefor |
| 09/12/2001 | EP1131344A2 Retro-inversion peptides that target git transport receptors and related methods |
| 09/12/2001 | EP1131340A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 09/12/2001 | EP1131334A1 Use of core 2 glcnac transferase inhibitors in treating inflammation |
| 09/12/2001 | EP1131322A2 Dihydropyridine compounds and methods of use |
| 09/12/2001 | EP1131317A1 Method for preparing (2s)-1- (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide |
| 09/12/2001 | EP1131315A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 09/12/2001 | EP1131314A1 Compounds having cytokine inhibitory activity |
| 09/12/2001 | EP1131304A1 N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| 09/12/2001 | EP1131302A1 Substituted 4-amino-2-aryl-cyclopenta d]pyrimidines, their production and use and pharmaceuticalreparations containing same |
| 09/12/2001 | EP1131301A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 09/12/2001 | EP1131295A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 09/12/2001 | EP1131294A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands |
| 09/12/2001 | EP1131293A1 1-aminoethylquinoline derivatives for treating urinary incontinence |
| 09/12/2001 | EP1131099A2 Noninvasive vascular therapy |
| 09/12/2001 | EP1131090A2 Method of using pon-1 to decrease atheroma formation |
| 09/12/2001 | EP1131086A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 09/12/2001 | EP1131085A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 09/12/2001 | EP1131082A2 A method for treating tissue damaged from ischemia |
| 09/12/2001 | EP1131073A1 Use of staurosporine derivatives for treating ocular neovascular diseases |
| 09/12/2001 | EP1131072A2 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide |
| 09/12/2001 | EP1131060A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 09/12/2001 | EP1131050A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 09/12/2001 | EP1044200A4 Preparation of terazosin hydrochloride dihydrate |
| 09/12/2001 | EP1032424B1 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
| 09/12/2001 | EP0929572A4 Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
| 09/12/2001 | EP0888317B1 Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma |
| 09/12/2001 | EP0832066B1 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| 09/12/2001 | EP0831864B1 Processed ginseng having enhanced pharmacological effect |
| 09/12/2001 | EP0822826B1 Nitrosylated neuropeptides |
| 09/12/2001 | EP0790987B1 Aminotetrazole derivatives useful as nitric oxide synthase inhibitors |
| 09/12/2001 | EP0749424B1 Naphthalene derivatives as prostaglandin i2 agonists |
| 09/12/2001 | EP0704056B1 Leukocyte adhesion assay |
| 09/12/2001 | CN1312807A Inhibitors of glycogen synthase kinase 3 |
| 09/12/2001 | CN1312805A Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 09/12/2001 | CN1312800A Therapeutic biaryl derivatives |
| 09/12/2001 | CN1312718A Selective estrogen receptor modulator in combination with sex steriod precursors and the like |
| 09/12/2001 | CN1312717A Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| 09/12/2001 | CN1312715A Antihypersensitive combination of valsartan and calcium channel blocker |
| 09/12/2001 | CN1312294A Human blood and blood vessel cytopoiesis hormone and its preparation |
| 09/12/2001 | CN1312246A Process for preparing carboxylic acid |
| 09/12/2001 | CN1312115A Apoplexy treating capsule and its preparation method |
| 09/12/2001 | CN1312112A Cure-all ointment |
| 09/12/2001 | CN1312108A Hypertension treating Chinese herbal medicine preparation |
| 09/12/2001 | CN1312095A Hypertension-treating medicine |
| 09/12/2001 | CN1312094A Medicine for treating heart disease and promoting recovery |
| 09/12/2001 | CN1312071A Linolic acid and linolenic acid capsule and its making process |
| 09/12/2001 | CN1070853C 10-acyloxy-10,11-dihydrodibenz/b,f/azepine-5-carboxamides useful for treating nervous system disorders |
| 09/12/2001 | CN1070849C Enzyme inhibitors |
| 09/12/2001 | CN1070841C Carboxylic acid derivatives, their preparation and their use |
| 09/12/2001 | CN1070701C Pyrimidine ortriazine carboxylic acid derivatives to be used as medicaments |
| 09/11/2001 | US6288278 Benzene derived amino alcohols as drugs |
| 09/11/2001 | US6288277 Drugs, antiarthritic agants, antihistamines for treatment of asthma |
| 09/11/2001 | US6288231 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 09/11/2001 | US6288228 Triazine angiogenesis inhibitors |
| 09/11/2001 | US6288123 Therapeutic guanidines |
| 09/11/2001 | US6288117 Administering triiodothyronine(t3) |
| 09/11/2001 | US6288110 Pharmaceutical compositions comprising disulfiram |
| 09/11/2001 | US6288103 Monocyte chemoattractant proteins antagonist such as n-(3-chlorophenylsulphonyl)indole-2-carboxylic acid; antiinflammatory agents |
| 09/11/2001 | US6288100 Benzimidazole derivatives |
| 09/11/2001 | US6288084 Administering comounds such as 4-(4-chlorophenyl)-1-(4-(3-methoxyphenyl)-4-(3-pyridinyl)-3 -butenyl)piperidin-4-ol to treat diseases associated with aberrant leukocyte recruitment and/or activation |
| 09/11/2001 | US6288083 Chemokine receptor antagonists and methods of use therefor |
| 09/11/2001 | US6288077 2,3-methano-amino acid compounds |
| 09/11/2001 | US6288075 Antiepileptic agents; nervous system, brain, and cardiovascular disorders |
| 09/11/2001 | US6288058 Treating muscular, nervous system, psychological and gastrointestinal disorders |
| 09/11/2001 | US6288056 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 09/11/2001 | US6288055 Analgesic agents |
| 09/11/2001 | US6288029 Template assembled synthetic peptide effective to treat respiratory system disorders |
| 09/11/2001 | US6287836 Histidine kinase from Streptococcus pneumoniae and compositions therecontaining |
| 09/11/2001 | US6287794 Peptide having antithrombotic effect through reversible inhibition of blood coagulation factor; antiinflammatory agents; treatment of cardiovascular disorders |
| 09/11/2001 | US6287786 Nucleic acid molecules encoding a new mammalian protein and to the use of these molecules in the characterization, diagnosis, and treatment of conditions such as disorders associated with cell proliferation, lipid metabolism and transport. |
| 09/11/2001 | US6287576 Biostimulating agent |
| 09/11/2001 | CA2115426C Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents |
| 09/11/2001 | CA2031570C Substituted cyclohexenes as central nervous system agents |
| 09/07/2001 | WO2001064907A2 Lipid metabolism enzymes |
| 09/07/2001 | WO2001064885A1 Chordin-like-2 molecules and uses thereof |
| 09/07/2001 | WO2001064884A2 G12l, a gene associated with the thermal response |
| 09/07/2001 | WO2001064879A2 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | WO2001064874A2 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 09/07/2001 | WO2001064870A2 Mutated cyclin g1 protein |
| 09/07/2001 | WO2001064862A1 Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof |
| 09/07/2001 | WO2001064847A2 In vitro modification of cardiac valvular xenografts |
| 09/07/2001 | WO2001064837A2 β NETRIN AND USES THEREOF |
| 09/07/2001 | WO2001064750A2 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 09/07/2001 | WO2001064743A1 GPib-LIPID BOND CONSTRUCT AND USE THEREOF |
| 09/07/2001 | WO2001064738A2 Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 09/07/2001 | WO2001064706A1 Antisense modulation of e2f transcription factor 1 expression |
| 09/07/2001 | WO2001064692A1 Cardioprotective phosphonates and malonates |
| 09/07/2001 | WO2001064691A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064679A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 09/07/2001 | WO2001064677A1 Novel imidazotriazinones and the use thereof |
| 09/07/2001 | WO2001064670A1 Novel cyclic amide derivatives |
| 09/07/2001 | WO2001064669A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | WO2001064668A2 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 09/07/2001 | WO2001064661A1 Antioxidants |
| 09/07/2001 | WO2001064655A1 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | WO2001064653A1 Pyrimidine compounds |
| 09/07/2001 | WO2001064646A2 Hydrazones and analogs as cholesterol lowering agents |